Phase III results of olaparib for BRCA breast cancer
4 Jun 2017
Phase III results of olaparib for BRCA breast cancer
Theory and application of electrochemotherapy
Deregulated TGF-β superfamily signalling in cancer
Functions of BRCA1 and the implications for treatment
Resistance to CDK4/6 inhibitors
Deciphering the connection of genetics, immune infiltration and prognosis
Transforming patient care through translational research
Mechanisms of resistance to CDK4/6 inhibitors in triple negative breast cancer
pSTAT3 in luminal breast cancer - results from BIG-2-98 trial
Centrosomes in ovarian cancer
Hallmarks of cancer cell development
IDH metabolites induce a BRCAness that can be exploited by PARP inhibitors